CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 5,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $65.00, for a total transaction of $325,000.00. Following the completion of the sale, the director owned 5,000 shares in the company, valued at approximately $325,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

CG Oncology Trading Down 0.8%

Shares of NASDAQ CGON opened at $65.73 on Wednesday. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $75.50. The firm has a 50-day moving average of $64.19 and a two-hundred day moving average of $57.53. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of -28.21 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, research analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Truist Financial restated a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Royal Bank Of Canada raised their price objective on CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wolfe Research started coverage on CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Monday, May 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, CG Oncology has a consensus rating of “Moderate Buy” and an average price target of $81.73.

Institutional Investors Weigh In On CG Oncology

Several hedge funds have recently bought and sold shares of the business. NFSG Corp acquired a new stake in CG Oncology during the 1st quarter worth about $34,000. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CG Oncology in the 4th quarter valued at about $27,000. Comerica Bank increased its holdings in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Fifth Third Bancorp purchased a new stake in shares of CG Oncology in the first quarter worth approximately $74,000. Finally, KBC Group NV purchased a new stake in shares of CG Oncology in the first quarter worth approximately $78,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.